Trimethoprim Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Alerts
• Clinical Trials
• Forums

Study of Subretinally Injected SAR439483 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D
Condition:   Leber's Congenital Amaurosis Interventions:   Drug: SAR439483;   Drug: SAR439483 Diluent Solution;   Drug: Prednisone;   Drug: Triamcinalone Acetonide;   Drug: 1% Prednisolone;   Drug: Trimethoprim/polymyxin B Sponsor:   Sanofi Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2019 Category: Research Source Type: clinical trials

TEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis With Polyangiitis
Conditions:   Granulomatosis With Polyangiitis;   Wegener Granulomatosis Intervention:   Drug: Trimethoprim Sulfamethoxazole Sponsor:   University of Pennsylvania Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2019 Category: Research Source Type: clinical trials

Study of Subretinally Injected SAR439483 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D
Condition:   Leber's Congenital Amaurosis Interventions:   Drug: SAR439483;   Drug: SAR439483 Diluent Solution;   Drug: Prednisone;   Drug: Triamcinalone Acetonide;   Drug: 1% Prednisolone;   Drug: Trimethoprim/polymyxin B Sponsor:   Sanofi Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2019 Category: Research Source Type: clinical trials

TEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis With Polyangiitis
Conditions:   Granulomatosis With Polyangiitis;   Wegener Granulomatosis Intervention:   Drug: Trimethoprim Sulfamethoxazole Sponsor:   University of Pennsylvania Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2019 Category: Research Source Type: clinical trials

Study of Subretinally Injected SAR439483 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D
Condition:   Leber's Congenital Amaurosis Interventions:   Drug: SAR439483;   Drug: SAR439483 Diluent Solution;   Drug: Prednisone;   Drug: Triamcinalone Acetonide;   Drug: 1% Prednisolone;   Drug: Trimethoprim/polymyxin B Sponsor:   Sanofi Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2019 Category: Research Source Type: clinical trials

TEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis With Polyangiitis
Conditions:   Granulomatosis With Polyangiitis;   Wegener Granulomatosis Intervention:   Drug: Trimethoprim Sulfamethoxazole Sponsor:   University of Pennsylvania Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2019 Category: Research Source Type: clinical trials

Study of Subretinally Injected SAR439483 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D
Condition:   Leber's Congenital Amaurosis Interventions:   Drug: SAR439483;   Drug: SAR439483 Diluent Solution;   Drug: Prednisone;   Drug: Triamcinalone Acetonide;   Drug: 1% Prednisolone;   Drug: Trimethoprim/polymyxin B Sponsor:   Sanofi Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2019 Category: Research Source Type: clinical trials

TEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis With Polyangiitis
Conditions:   Granulomatosis With Polyangiitis;   Wegener Granulomatosis Intervention:   Drug: Trimethoprim Sulfamethoxazole Sponsor:   University of Pennsylvania Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2019 Category: Research Source Type: clinical trials

Study of Subretinally Injected SAR439483 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D
Condition:   Leber's Congenital Amaurosis Interventions:   Drug: SAR439483;   Drug: SAR439483 Diluent Solution;   Drug: Prednisone;   Drug: Triamcinalone Acetonide;   Drug: 1% Prednisolone;   Drug: Trimethoprim/polymyxin B Sponsor:   Sanofi Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2019 Category: Research Source Type: clinical trials

TEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis With Polyangiitis
Conditions:   Granulomatosis With Polyangiitis;   Wegener Granulomatosis Intervention:   Drug: Trimethoprim Sulfamethoxazole Sponsor:   University of Pennsylvania Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2019 Category: Research Source Type: clinical trials

Study of Subretinally Injected SAR439483 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D
Condition:   Leber's Congenital Amaurosis Interventions:   Drug: SAR439483;   Drug: SAR439483 Diluent Solution;   Drug: Prednisone;   Drug: Triamcinalone Acetonide;   Drug: 1% Prednisolone;   Drug: Trimethoprim/polymyxin B Sponsor:   Sanofi Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2019 Category: Research Source Type: clinical trials

TEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis With Polyangiitis
Conditions:   Granulomatosis With Polyangiitis;   Wegener Granulomatosis Intervention:   Drug: Trimethoprim Sulfamethoxazole Sponsor:   University of Pennsylvania Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2019 Category: Research Source Type: clinical trials

Study of Subretinally Injected SAR439483 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D
Condition:   Leber's Congenital Amaurosis Interventions:   Drug: SAR439483;   Drug: SAR439483 Diluent Solution;   Drug: Prednisone;   Drug: Triamcinalone Acetonide;   Drug: 1% Prednisolone;   Drug: Trimethoprim/polymyxin B Sponsor:   Sanofi Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2019 Category: Research Source Type: clinical trials